{"id":"NCT02018627","sponsor":"Steven J. Russell, MD, PhD","briefTitle":"Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon","officialTitle":"Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-04","primaryCompletion":"2018-08-02","completion":"2018-08-02","firstPosted":"2013-12-23","resultsPosted":"2019-10-08","lastUpdate":"2019-10-08"},"enrollment":20,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes"],"interventions":[{"type":"DRUG","name":"Xeris glucagon","otherNames":[]},{"type":"DRUG","name":"Lilly glucagon","otherNames":[]}],"arms":[{"label":"Xeris glucagon","type":"EXPERIMENTAL"},{"label":"Lilly glucagon","type":"ACTIVE_COMPARATOR"}],"summary":"This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of Glucagon for Injection (Eli Lilly).","primaryOutcome":{"measure":"Tmax","timeFrame":"every 2 minutes for 1 hour post-dose of each glucagon","effectByArm":[{"arm":"Xeris Glucagon","deltaMin":23.8,"sd":9.3},{"arm":"Lilly Glucagon","deltaMin":15.7,"sd":3}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":11},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":[]}}